Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma

Sitravatinib is an immunomodulatory tyrosine kinase inhibitor that can augment responses when combined with programmed death-1 inhibitors such as nivolumab. We report a single-arm, interventional, phase 2 study of neoadjuvant sitravatinib in combination with nivolumab in patients with locally advanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Karam, Jose A., Msaouel, Pavlos, Haymaker, Cara L., Matin, Surena F., Campbell, Matthew T., Zurita, Amado J., Shah, Amishi Y., Wistuba, Ignacio I., Marmonti, Enrica, Duose, Dzifa Y., Parra, Edwin R., Soto, Luisa Maren Solis, Laberiano-Fernandez, Caddie, Lozano, Marisa, Abraham, Alice, Hallin, Max, Chin, Curtis D., Olson, Peter, Der-Torossian, Hirak, Yan, Xiaohong, Tannir, Nizar M., Wood, Christopher G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172300/
https://www.ncbi.nlm.nih.gov/pubmed/37164948
http://dx.doi.org/10.1038/s41467-023-38342-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172300/
https://www.ncbi.nlm.nih.gov/pubmed/37164948
http://dx.doi.org/10.1038/s41467-023-38342-7

Ejemplares similares